ALX Oncology Holdings Inc. (ALXO)
| Market Cap | 138.28M +39.6% |
| Revenue (ttm) | n/a |
| Net Income | -80.89M |
| EPS | -0.93 |
| Shares Out | 138.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,709,790 |
| Open | 0.911 |
| Previous Close | 0.895 |
| Day's Range | 0.862 - 1.020 |
| 52-Week Range | 0.862 - 2.660 |
| Beta | 0.48 |
| Analysts | Strong Buy |
| Price Target | 4.60 (+360.0%) |
| Est. Earnings | Nov 6, 2026 |
About ALXO
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of bre... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for ALXO stock is "Strong Buy." The 12-month stock price target is $4.6, which is an increase of 360.00% from the latest price.
News
ALX Oncology announces publication of data from ASPEN-06 Phase 2 trial
ALX Oncology (ALXO) announced the publication of clinical data from its ASPEN-06 randomized Phase 2 clinical trial in Nature Medicine. The Nature Medicine publication, titled “Evorpacept plus trastuzu...
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression ...
ALX Oncology Holdings Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Two lead programs are advancing toward pivotal studies, with evorpacept showing strong biomarker-driven efficacy and ALX2004 progressing through dose escalation in multiple tumor types. Financial runway supports operations through mid-2028, and companion diagnostic development is ongoing.
ALX Oncology Holdings Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Two oncology programs are advancing: a CD47-targeted therapy with strong biomarker-driven results in HER2+ and CD47 high cancers, and an EGFR ADC with a unique epitope and promising safety profile. Both address significant unmet needs, with pivotal data and companion diagnostics expected to shape future trials.
ALX Oncology Holdings Transcript: Wells Fargo 21st Annual Healthcare Conference
ALX2004 is advancing through dose escalation with promising safety and activity signals, aiming for expansion and registrational studies next year. Evorpacept shows strong efficacy in CD47-high breast cancer patients, with robust enrollment and a clear path to phase III. Both programs are funded through mid-2028 and target significant unmet needs in oncology.
ALX Oncology to Present at Upcoming Investor Conferences in September
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapie...
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive meta...
ALX Oncology Holdings Earnings release: Q2 2026
ALX Oncology Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
ALX Oncology Holdings Quarterly report: Q2 2026
ALX Oncology Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies...
ALX Oncology chairman Corey Goodman steps down, Scott Garland succeeds
ALX Oncology (ALXO) announced the appointments of Scott Garland as chairman of the board of directors and Michael Listgarten as general counsel, effective immediately. Garland succeeds Corey Goodman, ...
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph.D., After More Than a Decade of Foundational Leadership SOUTH SAN...
ALX Oncology Holdings Transcript: AGM 2026
Directors and management were introduced, and all voting proposals—including director elections, executive compensation, and auditor ratification—were approved. Clinical programs evorpacept and ALX2004 showed progress, with key data readouts expected in the next 12-18 months.
ALX Oncology Holdings Transcript: Jefferies Global Healthcare Conference 2026
Two clinical programs are advancing: evorpacept, showing strong efficacy in HER2-positive cancers, and ALX2004, a differentiated EGFR ADC with promising safety and dose escalation. ASPEN-09 phase II will refine CD47 biomarker strategy, with key data and regulatory discussions expected next year.
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies ...
ALX Oncology Holdings Earnings Call Transcript: Q1 2026
New data show evorpacept plus zanidatamab delivers high response rates and durable benefit in heavily pre-treated HER2-positive breast cancer, especially in CD47-high patients. ASPEN-09 and ALX2004 trials are progressing on schedule, with strong financial backing and leadership.
ALX Oncology Holdings Earnings release: Q1 2026
ALX Oncology Holdings released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
ALX Oncology Holdings Slides: Q1 2026
ALX Oncology Holdings has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 8, 2026.
ALX Oncology Holdings Quarterly report: Q1 2026
ALX Oncology Holdings has published its Q1 2026 quarterly earnings report on May 8, 2026.
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable resp...
ALX Oncology evorpacept combination data presented at ESMO congress
ALX Oncology (ALXO) announced that data from exploratory analyses in the Phase 1b/2 clinical trial evaluating the company’s investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceu...
ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept -
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasda...
ALX Oncology Holdings Proxy statement: Proxy filing
ALX Oncology Holdings filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
ALX Oncology appoints Jeff Knight as chief development, operating officer
ALX Oncology (ALXO) announced the appointment of Jeff Knight as chief development and operating officer, effective April 13. Most recently, he served as chief development and operating officer at Crin...